Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/28714
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Walia, N | - |
dc.contributor.author | Eratne, Dhamidhu | - |
dc.contributor.author | Loi, S M | - |
dc.contributor.author | Li, Q-X | - |
dc.contributor.author | Varghese, S | - |
dc.contributor.author | Malpas, C B | - |
dc.contributor.author | Walterfang, Mark | - |
dc.contributor.author | Evans, A H | - |
dc.contributor.author | Parker, S | - |
dc.contributor.author | Collins, S J | - |
dc.contributor.author | Masters, C L | - |
dc.contributor.author | Velakoulis, D | - |
dc.date | 2021 | - |
dc.date.accessioned | 2022-02-01T04:44:52Z | - |
dc.date.available | 2022-02-01T04:44:52Z | - |
dc.date.issued | 2022-01-15 | - |
dc.identifier.citation | Journal of the Neurological Sciences 2022; 432: 120088 | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/28714 | - |
dc.description.abstract | Determining disease severity and predicting prognosis in younger onset-dementia (YOD) remains challenging. Whether CSF biomarkers neurofilament light (NfL), tau and amyloidβ 42 (Aβ42) can help provide such information has been underexplored. Patients with YOD and CSF analysis were identified. We compared baseline NfL, tau and Aβ42 concentrations with contemporaneous Neuropsychiatry Unit Cognitive Assessment Tool (NUCOG) scores to assess their association with severity of cognitive impairment. Cognitive decline, as measured by longitudinal NUCOG assessment, was correlated against baseline biomarker levels to assess their utility in predicting the rate of cognitive decline. 78 patients with YOD (mean age = 56 years, SD = 8) and CSF analysis were identified. Dementia types included Alzheimer's disease, behavioural variant frontotemporal dementia, dementia not-otherwise-specified and other. Tau was associated with contemporaneous memory dysfunction (r = -0.556, 95% CI:[-0.702,-0.393], p < .001). 21 patients had longitudinal cognitive assessment up to 82 months from CSF sampling. NfL was associated with the rate of executive function decline (r = 0.755, 95% CI:[0.259,0.937], p < .001). Aβ42 was associated with the rate of memory decline (r = -0.582, 95% CI:[-0.855,-0.274], p = .007) and rate of total NUCOG decline (r = -0.515, 95% CI: [-0.809, -0.227], p = .017). CSF tau is related to contemporaneous memory impairment in YOD. NfL and Aβ42 levels are associated with the rate of executive function and memory decline, respectively, and may have a role in prognostication in YOD. | en |
dc.language.iso | eng | |
dc.subject | CSF biomarkers | en |
dc.subject | Cognitive decline | en |
dc.subject | Neurofilament light | en |
dc.subject | Tau | en |
dc.subject | Younger-onset dementia | en |
dc.subject | amyloidβ 42 | en |
dc.title | Cerebrospinal fluid neurofilament light predicts the rate of executive function decline in younger-onset dementia. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Journal of the Neurological Sciences | en |
dc.identifier.affiliation | The Florey Institute of Neuroscience and Mental Health | en |
dc.identifier.affiliation | National Dementia and Diagnostics Laboratory, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia | en |
dc.identifier.affiliation | Department of Neurology, The Royal Melbourne Hospital, Parkville, VIC, Australia | en |
dc.identifier.affiliation | Melbourne Neuropsychiatry Centre & Department of Psychiatry, The University of Melbourne, Parkville, VIC, Australia | en |
dc.identifier.affiliation | Department of Medicine (RMH), The University of Melbourne, Parkville, VIC, Australia | en |
dc.identifier.affiliation | Melbourne Medical School, The University of Melbourne, Parkville, VIC, Australia | en |
dc.identifier.affiliation | Clinical Outcomes Research Unit (CORe), Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Parkville, VIC, Australia | en |
dc.identifier.affiliation | Neuropsychiatry, The Royal Melbourne Hospital, Parkville, VIC, Australia | en |
dc.identifier.doi | 10.1016/j.jns.2021.120088 | en |
dc.type.content | Text | en |
dc.identifier.orcid | 0000-0002-1389-3691 | en |
dc.identifier.orcid | 0000-0002-3226-7645 | en |
dc.identifier.orcid | 0000-0001-8438-3763 | en |
dc.identifier.orcid | 0000-0002-5245-6611 | en |
dc.identifier.orcid | 0000-0003-3072-7940 | en |
dc.identifier.pubmedid | 34922179 | |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.